Stellar ushers in new common stock to take over Canadian firm; will also take over its name
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar reports decline in third quarter earnings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar Biotechnologies narrows net losses
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar Biotechnologies stock up 21 percent after announcement
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar Biotechnologies announces 1-for-7 reverse stock split
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Revenues down at Stellar Biotechnologies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Stellar Biotechnologies revenues fall in third quarter
Revenues for Port Hueneme-based immunotherapy developer Stellar Biotechnologies fell to $20,000 for its fiscal third quarter, about a ninth what it was for the same quarter the prior year. The slump in sales was a product of lower volume orders for the three months ended June 30, the company said in an earnings release Aug. Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
